Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens

Virginia Powers, PhD
Published: Saturday, Jun 24, 2017

Grade ≥2 neurological toxicity was greater in the thalidomide-containing regimen, with sensory peripheral neuropathy being reported 2.9%, 3.6%, and 9.5% of patients in the quadruplet, triplet, and CTD cohorts, respectively. There was no statistically significant difference observed in rates of investigator-reported, all grade thromboembolic events between regimens.

Cardiac events including arrhythmias, heart failure, and hypertension occurred in fewer than 3% of patients.

“Induction therapy with KCRD, an outpatient delivered quadruplet regimen, was associated with deeper responses than either immunomodulatory triplet therapy, and was well tolerated,” said Pawlyn. “KCRD induction achieved a high rate of response in newly diagnosed transplant-eligible patients and the depth of response was consistent across all risk groups.”
Pawlyn C, et al. Quadruplet vs sequential triplet induction therapy for myeloma patients: results of the Myeloma XI study. Presented at: 22nd Annual European Hematology Association Congress; June 22-25, 2017; Madrid, Spain. Abstract S407.


<<< More from the 2017 EHA Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x